Introduction
Methods
Study population
Measurements
Protocol and data analysis
Results
Baseline values
Variable | RHT–RDN | RHT–control |
---|---|---|
(n = 14) | (n = 10) | |
Age (years) | 58.3 ± 2.2 | 59.1 ± 2.6 |
Gender (males/females, n) | 11/3 | 8/2 |
BMI (kg/m2) | 26.7 ± 0.7 | 26.9 ± 1.0 |
Clinic blood pressure (S/D, mmHg) | 169.4 ± 3.9/94.8 ± 3.4 | 166.1 ± 3.4/95.5 ± 3.3 |
Clinic heart rate (beats/min) | 69.1 ± 3.5 | 67.5 ± 3.1 |
24-h blood pressure (S/D, mmHg) | 160.1 ± 3.2/90.4 ± 3.0 | 159.5 ± 3.3/90.1 ± 3.2 |
24-h heart rate (beats/min) | 65.4 ± 3.1 | 64.1 ± 2.9 |
LVEF (%) | 60.2 ± 1.1 | 59.9 ± 1.2 |
LVMI (g/m2) | 115.5 ± 3.9 | 114.3 ± 0.2 |
E/A ratio, a.u | 0.99 ± 0.1 | 0.98 ± 0.1 |
eGFR (ml/min/1.73 m2) | 79.3 ± 3.0 | 80.4 ± 3.4 |
Respiration rate (breaths/min) | 17.4 ± 0.6 | 17.8 ± 0.7 |
MSNA (bursts/min) | 45.6 ± 2.3 | 46.2 ± 2.8 |
MSNA (bursts/100 hb) | 68.1 ± 2.5 | 70.3 ± 3.9 |
SSNA (bursts/min) | 13.1 ± 0.5 | 13.8 ± 0.6 |
Anti-HT drugs (n/day) | 4.4 ± 0.5 | 4.6 ± 0.7 |
ACEIs | 74.0% | 71.8% |
ARBs | 66.6% | 63.5% |
β-blockers | 68.9% | 69.3% |
α-blockers | 22.4% | 24.4% |
Calcium blockers | 67.4% | 69.1% |
Diuretics | 100.0% | 100.0% |
Centrally acting drugs | 42.3% | 44.8% |
Aldosterone antagonists | 45.8% | 50.0% |
Effects of RDN
Control group
Variable | Baseline | 1-month FU | 3-month FU |
---|---|---|---|
Clinic SBP (mmHg) | 166.1 ± 3.4 | 169.4 ± 3.8 | 170.1 ± 3.8 |
Clinic DBP (mmHg) | 95.5 ± 3.3 | 94.8 ± 3.5 | 96.1 ± 3.4 |
Clinic HR (beats/min) | 67.5 ± 3.1 | 68.4 ± 2.8 | 68.0 ± 3.0 |
24-h SBP (mmHg) | 159.5 ± 3.3 | 161.9 ± 3.2 | 163.5 ± 3.4 |
24-h DBP (mmHg) | 90.1 ± 3.2 | 89.5 ± 3.1 | 91.3 ± 3.3 |
24-h HR (beats/min) | 64.1 ± 2.9 | 67.2 ± 3.0 | 67.4 ± 2.8 |
Resp rate (breaths/min) | 17.8 ± 0.7 | 17.4 ± 0.5 | 17.6 ± 0.7 |
Anti-HT drugs (n/day) | 4.6 ± 0.7 | 4.7 ± 0.7 | 4.7 ± 0.8 |
MSNA (bursts/min) | 48.2 ± 2.3 | 49.4 ± 2.4 | 49.9 ± 2.3 |
MSNA (bursts/100 hb) | 70.3 ± 3.9 | 70.9 ± 3.8 | 72.8 ± 3.9 |
SSNA (bursts/min) | 13.8 ± 0.6 | 14.5 ± 0.6 | 14.2 ± 0.5 |